Starting a new standard of care using targeted transdermal technology. We are committed to developing products with superior efficacy, reduced toxicities against approved medicines in hematological malignancies.

Targeted transdermal delivery

Each product we work on is reimagined and studied to develop new dose regimens and define optimal targets. Our approach establishes new indications and delivers superior outcomes.

Careers

We are building a team dedicated to delivering breakthrough, transformative outcomes for patients with hematological malignancies. Learn more about career opportunities at Starton.

News and Events

04/30/20

Starton Therapeutics Files PCT and US Patent Application for Continuous Delivery of Lenalidomide and Class of Immunomodulatory Agents

NEW YORK, N.Y., April 30, 2020 – Starton Therapeutics Inc. (“Starton” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced that it has…

12/27/19

Starton Successfully Completes Proof of Concept Study for Transdermal Lenalidomide

NEW YORK, Dec. 27, 2019 (GLOBE NEWSWIRE) — Starton Therapeutics Inc. (“Starton” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced the completion…